377 related articles for article (PubMed ID: 32312906)
1. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
2. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
[TBL] [Abstract][Full Text] [Related]
3. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
4. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
7. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
10. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
11. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
[TBL] [Abstract][Full Text] [Related]
12. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
13. Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer.
Teranishi S; Kobayashi N; Katakura S; Kamimaki C; Kubo S; Shibata Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Apr; 11(4):983-992. PubMed ID: 32067413
[TBL] [Abstract][Full Text] [Related]
14. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
15. Prostasin regulates PD-L1 expression in human lung cancer cells.
Chen LM; Chai JC; Liu B; Strutt TM; McKinstry KK; Chai KX
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34240739
[TBL] [Abstract][Full Text] [Related]
16.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
17. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.
Padmanabhan S; Zou Y; Vancurova I
Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184
[TBL] [Abstract][Full Text] [Related]
19. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
Hirayama A; Tanaka K; Tsutsumi H; Nakanishi T; Yamashita S; Mizusaki S; Ishii Y; Ota K; Yoneshima Y; Iwama E; Okamoto I
Front Immunol; 2023; 14():1192861. PubMed ID: 37441079
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
